A single-arm open-label, phase II trial, assessing the safety and efficacy of short-course radiotherapy (5 × 5 Gy) and Toripalimab as a novel bladder sparing treatment in patients with high-risk / extremely high risk NMIBC
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Toripalimab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOPE-04
Most Recent Events
- 15 Jul 2024 New trial record